Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | VCAM1 | P19320 | 9/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM4B | O94953 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115822 | 0.85 | TDP1 (0.62) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL5583401 | 0.83 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL14159967 | 0.81 | TDP1 (0.44) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL29137985 | 0.81 | TDP1 (0.44) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL31503808 | 0.78 | ALDH1A1 (0.49) | TDP1ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL9693348 | 0.78 | ALDH1A1 (0.45) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL278488 | 0.77 | TDP1 (1.00) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL103575 | 0.77 | TDP1 (0.59) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL9694013 | 0.75 | ALDH1A1 (0.67) | MAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL11811233 | 0.74 | TDP1 (0.71) | TDP1VCAM1TSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107903217-B | Preparation method of anagrelide impurity B | 湖北省宏源药业科技股份有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-107903217-A | A kind of preparation method of anagrelide impurity B | 湖北省宏源药业科技股份有限公司 | 2018-04-13 | — | — | CN | claimed |
| CN-103333078-A | Synthesis method for key intermediate, analogue or salt of ticlopidine | SUZHOU HUIHE PHARMACEUTICAL CO LTD | 2013-10-02 | — | — | CN | claimed |
| WO-2024026536-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2024-02-08 | — | — | WO | disclosed |
| CN-107903217-B | Preparation method of anagrelide impurity B | 湖北省宏源药业科技股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-2630148-B1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE LLC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-2630148-B1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE LLC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-1836202-B1 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2016-12-21 | — | — | EP | disclosed |
| CN-102272105-B | enantiomerically enriched aryloazol-2-yl cyanoethylamino parasiticidal compounds | 梅瑞尔公司 | 2016-09-14 | — | — | CN | disclosed |
| CN-103180323-B | For the method preparing anagrelide and the like | 夏尔有限责任公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-103483263-B | Arylpyrrol-2-yl cyanoethylamino compounds, process for their preparation and their use | MERIAL LTD. (US) | 2016-04-13 | — | — | CN | disclosed |
| US-6653500-B2 | Making ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine from 2,3-dichlorobenzaldehyde, reducing the glycine compound using tin dichloride or a catalyst and cyclization of the corresponding iminoquinazoline compound | SHIRE US INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030114673-A1 | 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES | SHIRE US INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030060630-A1 | Method for the manufacture of Anagrelide | SHIRE US INC. | 2003-03-27 | — | — | US | disclosed |
| US-6388073-B1 | NITRATION A 3,4-DICHLOROBENZALDEHYDE; REDUCING; CHLORINATION; ALKYLATION; BROMOCYANATION; CHLIZATION | SHIRE US INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2002008228-A2 | METHOD FOR THE MANUFACTURE OF ANAGRELIDE | SHIRE US INC (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001040196-A1 | 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES | ROBERTS LABORATORIES INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6194420-B1 | BLOOD DISORDERS; REDUCE PLATELET CONCENTRATION | ROBERTS LABORATORIES INC. | 2001-02-27 | — | — | US | disclosed |
| EP-0736032-A1 | HETEROCYCLIC COMPOUNDS | Astra Aktiebolag (SE) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017410-A1 | HETEROCYCLIC COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114673-A1 | 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES | THPO, F2, PF4 | TDP1 520/4885VCAM1 2606/4885TSHR 3625/4885 |
| US-20030060630-A1 | Method for the manufacture of Anagrelide | SUCLG2, PDCD2L, ICOSLG | TDP1 2354/4885VCAM1 2537/4885TSHR 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.